• Welcome to Phoenix Rising!

    Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of and finding treatments for complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia (FM), long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

    To become a member, simply click the Register button at the top right.

Belimumab for Systemic Lupus


Senior Member
Sydney, NSW, Australia

"Clin Pharmacol Ther. 2011 Nov 30. doi: 10.1038/clpt.2011.290. [Epub ahead of print]
Belimumab: A BLyS-Specific Inhibitor for the Treatment of Systemic Lupus Erythematosus.
Dennis GJ.

Department of Medical Affairs, Human Genome Sciences, Rockville, Maryland, USA.

Belimumab (Benlysta), which recently received marketing approval, is the first of a new class of immunomodulators with a novel mechanism of action. It is a specific inhibitor of the soluble B-lymphocyte stimulator (BLyS) cytokine, which has been implicated in the pathogenesis of systemic lupus erythematosus (SLE). Two large phase III randomized controlled clinical trials evaluated the safety and efficacy of belimumab combined with standard therapy and showed that the efficacy of this treatment was significantly superior to placebo plus standard therapy. Belimumab is an evidence-based therapeutic option for patients with general lupus disease activity and may signal a shift in the existing treatment paradigm from therapeutic selection targeting specific organ involvement to an approach directed at tackling multisystem disease activity and preventing the disease from worsening.

[PubMed - as supplied by publisher] "

Snow Leopard

South Australia
I haven't read the paper, but this sounds interesting and should have lower side effects than other less specific treatments. It would be nice to see this drug approved by insurance companies for Lupus!